(Q36046256)

11 August 2017

1 reference

title

Utilizing prognostic and predictive factors in breast cancer (English)

1 reference

11 August 2017

1 reference

2

Claudine Isaacs

1 reference

11 August 2017

Deepa S Subramaniam

1

1 reference

11 August 2017

1 March 2005

1 reference

Current Treatment Options in Oncology

11 August 2017

1 reference

11 August 2017

6

1 reference

11 August 2017

2

1 reference

11 August 2017

147-159

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-005-0022-1

11 August 2017

0 references

cites work

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11864-005-0022-1

Redefining prognosis in node-negative breast cancer: can sentinel lymph node biopsy raise the threshold for systemic adjuvant therapy?

21 January 2018

1 reference

12 December 2020

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer

1 reference

12 December 2020

The prognostic value of lymphatic and blood vessel invasion in operable breast cancer

1 reference

12 December 2020

Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer

1 reference

12 December 2020

Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up

1 reference

12 December 2020

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

12 December 2020

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

12 December 2020

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

12 December 2020

Occult axillary lymph node metastases are of no prognostic significance in breast cancer

1 reference

12 December 2020

c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study

1 reference

12 December 2020

Cancer statistics, 2004

1 reference

12 December 2020

Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report

1 reference

12 December 2020

Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study

1 reference

12 December 2020

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

1 reference

12 December 2020

The Nottingham prognostic index in primary breast cancer

1 reference

12 December 2020

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15

1 reference

12 December 2020

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

12 December 2020

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Micrometastases in axillary lymph nodes and bone marrow of lymph node-negative breast cancer patients--prognostic relevance after 10 years

1 reference

12 December 2020

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.

1 reference

12 December 2020

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

1 reference

12 December 2020

Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer

1 reference

12 December 2020

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

1 reference

12 December 2020

The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer

1 reference

12 December 2020

Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas

1 reference

12 December 2020

Frequency of sentinel lymph node metastases in patients with favorable breast cancer histologic subtypes.

1 reference

12 December 2020

Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.

1 reference

12 December 2020

Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer

1 reference

12 December 2020

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

1 reference

12 December 2020

S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer

1 reference

12 December 2020

Time-dependence of hazard ratios for prognostic factors in primary breast cancer

1 reference

12 December 2020

Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06

1 reference

12 December 2020

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

1 reference

12 December 2020

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

1 reference

12 December 2020

Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis

1 reference

12 December 2020

Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group

1 reference

12 December 2020

Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications

1 reference

12 December 2020

Management and survival of female breast cancer: results of a national survey by the American College of Surgeons

1 reference

12 December 2020

Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases

1 reference

12 December 2020

S-phase fraction and breast cancer--a decade of experience

1 reference

12 December 2020

Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas

1 reference

12 December 2020

Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group

1 reference

12 December 2020

A review of selective estrogen receptor modulators and national surgical adjuvant breast and bowel project clinical trials

1 reference

12 December 2020

A gene-expression signature as a predictor of survival in breast cancer

1 reference

12 December 2020

Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer

1 reference

12 December 2020

A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy.

1 reference

12 December 2020

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer

1 reference

12 December 2020

HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study

1 reference

12 December 2020

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

1 reference

12 December 2020

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

1 reference

12 December 2020

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

1 reference

12 December 2020

Revision of the American Joint Committee on Cancer staging system for breast cancer

1 reference

12 December 2020

National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

1 reference

12 December 2020

10.1007/S11864-005-0022-1

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15717996